Abstract 333P
Background
FDG-PET/CT and Thallium SPECT (TL) which are radioisotope examination are inspection used as diagnostic imaging in the malignant tumors conventionally, and it is reported when useful for a stage diagnosis of the lung cancer. It was common to use the CT imaging according to the RECIST criteria for the effect judgment of cytotoxic agents and molecular target agents. In determining the efficacy of immune checkpoint inhibitors (ICIs), we often experienced that the assessment on CT imaging and the true effect do not match. Therefore, we planned a prospective study to evaluate whether FDG-PET/CT and TL examination is useful for ICI effect judgment. We examined the correlation between SUV differences on PET examination before treatment and 2 months after treatment initiation and RECIST evaluation.
Methods
A total of 18 advanced NSCLC patients treated at Kansai Medical University Hospital from September 2017 to September 2018 using ICI monotherapy were enrolled in this study. We examined the correlation with a PERCIST response rate and the response rate that went to the CT evaluation using RECIST1.1.
Results
The median age was 74 years. There were 15 men and three women. 15 cases were evaluable both before and two months after treatment initiatoin. There were CR/PR/SD/PD;0/3/7/5 by RECIST evaluation, and the curative effect judgment by FDG-PET were CMR/PMR/SMD/PMD; 1/3/6/5. 1 case was PD in RECIST, but was PMR in FDG-PET.The PR case tended to be higher in Tl accumulation after the treatment than an SD and PD cases.
Conclusions
The effect measurement by FDG-PET showed usefulness with more than that of RECIST evaluation and Tl-SPECT seems to have the potential to be useful in determining the effect of ICIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Takayasu Kurata.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract